Eikon Therapeutics, Inc.
EIKNNASDAQHealthcareBiotechnology
As of Oct 23, 2026 close
- Market cap
- $393.08M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $6.45$17.40
- Volume (live)
- -
- Avg. volume (3M)
- 600.51K
Eikon Therapeutics (EIKN) Stock Price & Financial Analysis
Eikon Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $7.20 - $8.07 |
|---|---|
| 52-Week High | $17.40 |
| 52-Week Low | $6.45 |
| Open | $8.07 |
| Volume (last close) | 318.32K |
| Average Volume (3M) | 600.51K |
| 50-Day MA | $9.31 |
|---|
| Market Cap | 393.08M |
|---|---|
| Shares Outstanding | 54.14M |
| Price to Book (P/B) | 0.84 |
| EV/EBITDA | -1.87 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
Eikon Therapeutics at a Glance
As of the Oct 23, 2026 close, Eikon Therapeutics (EIKN) has a market capitalization of $393.08M.
As of its latest reported balance sheet, it holds $142.61M in cash and securities against $252.22M of debt, a net debt position of $109.61M.
Eikon Therapeutics does not currently pay a dividend.
At $7.26 (the Oct 23, 2026 close) it sits near the bottom of its 52-week range of $6.45 to $17.40.
Based on 4 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $29.00, 299.4% above the Oct 23, 2026 close.
Frequently Asked Questions About Eikon Therapeutics
What is the current stock price for EIKN?
As of the Oct 23, 2026 close, EIKN stock trades at $7.26. The 52-week range is $6.45–$17.40, with a day range of $7.20–$8.07.
What is the P/E ratio for EIKN?
The P/E ratio (Price-to-Earnings) for EIKN is shown in the Key Statistics section. This valuation metric helps compare Eikon Therapeutics, Inc. to industry peers.
Does EIKN pay dividends?
Eikon Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for EIKN?
Based on ratings from 4 professional analysts over the last 90 days, the consensus for EIKN is Buy. The average 12-month price target is $29.00, a 299.4% upside from the Oct 23, 2026 close of $7.26.
What is the market cap of EIKN?
As of the Oct 23, 2026 close, Eikon Therapeutics's market capitalization is $393.1M, classifying it as a small-cap company. Eikon Therapeutics operates in the Healthcare sector within the Biotechnology industry.